The private placement included 700,000,000 ordinary shares

Davis Polk advised the joint global coordinators, joint bookrunners and co-managers in connection with a secondary private placement by Pfizer Inc. of 700,000,000 ordinary shares in Haleon plc. The private placement raised gross proceeds to Pfizer of approximately $3 billion.

Haleon plc, which is listed on the London Stock Exchange, is a global leader in consumer health, with a purpose to deliver better everyday health with humanity. Haleon’s product portfolio spans five major categories – oral health, pain relief, respiratory health, digestive health and other, and vitamins, minerals and supplements. Its long-standing brands include Advil, Sensodyne, Panadol, Voltaren, Theraflu, Otrivin, Polident, parodontax and Centrum.

The Davis Polk corporate team included partner Connie I. Milonakis and associate Serdar Inci. All members of the Davis Polk team are based in the London office.

 

Copy link to share post